Ranking Invest

Nuvalent, Inc.

Segmento: Healthcare Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Indicadores Básicos

Valor de Mercado

$ 5.41 Bi

IVR

0.09

IVR2

-0.10

Índices de Previsibilidade

Faturamento

0.00

Lucro

2.96

Margem

0.00

Índices de Tendência

Faturamento

0.00

Lucro

-11.01

Margem

0.00

Índices de Endividamento

DIV/PAT

-0.12

DIV/L4T

0.40

Dívida Líquida

-$ 120.83 Mi

Patrimônio Líquido

$ 1.01 Bi

L4T

-$ 300.86 Mi

MM4T

0.00%

Dívidas
Dividendos
Cotação: $74.67

Não há dados de histórico de dividendos para exibir.

Gráfico Lucro/Faturamento X Trimestre